Navigation Links
TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
Date:9/10/2013

TAIPEI, Sept. 10, 2013 /PRNewswire/ -- TWi Biotechnology, Inc., today announced that it has received an official notification of patent allowance for AC-201, TWi Biotechnology's lead drug candidate, from the United States Patent & Trademark Office. The granted patent, US patent number 8,536,152, covers AC-201's use as a combination therapy with other existing blood glucose lowering therapy agents to treat Type II diabetes. The patent is part of TWi Biotechnology's broad intellectual property portfolio for AC-201.

"We are very pleased with the issuance of this patent in United States for AC-201. This is the third patent TWi Biotechnology has received this year for our diabetes franchise," said Dr. Calvin C. Chen, President of TWi Biotechnology. "This new issuance provides TWi Biotechnology the intellectual property protection needed for AC-201 to address an unmet medical need for an effective treatment for chronic type II diabetes. Currently, the first line treatment for blood glucose therapy is metformin or sulfonylurea monotherapy. However, monotherapy with metformin or sulfonylurea still has limited benefit. Many patients fail to achieve the treatment goal after going through an extended treatment period. Our AC-201, in combination with existing blood glucose lowering therapy agents including metformin, has demonstrated its efficacy of reducing HbA1c levels in type 2 diabetic patients in two phase II clinical trials. TWi Biotechnology had presented the results of a 259-patient multinational phase IIb study in the American Diabetes Association 73rd Scientific Sections in Chicago, USA."

About AC-201

AC-201 is a first-in-class, orally available small molecule which has shown the ability to inhibit the production and activity of the cytokine IL-1Beta and to down-regulate the IL-1Beta receptors. Inhibition of IL-1Beta signaling has been demonstrated to be effective in treating a variety of diseases including arthritis and diabetic mellitus (DM). The active ingredient of AC-201 has been approved for treating patients with chronic rheumatic diseases in France and subsequently in other EU and Middle Eastern countries such as Spain and Italy since mid-1990.

TWi Biotechnology holds two US INDs for AC-201 – one for controlling blood glucose in type 2 diabetic patients and the other for gout flare prevention in patients under urate-lowering therapy. In addition to the good safety record of its active ingredient used in treating another chronic disease, AC-201 has gone through several human clinical trials including two phase II trials with 6 month treatment periods with a satisfactory safety profile.

About Type 2 Diabetes

Diabetes is one of the most common metabolic diseases worldwide. According to a June 2011 Lancet publication by Danaei and colleagues, the number of adults diagnosed with diabetes worldwide in 2008 was a staggering 347 million and this number is expected to rise to 472 million by 2030. World Health Organization (WHO) has defined type 2 diabetes as the result of the body's ineffective use of insulin. Type 2 diabetes comprises 90% of people with diabetes around the world, and is largely caused by excess body weight and physical inactivity. The American Diabetes Association estimated that in 2012, the total cost associated with diabetes in US was US$245 billion of which US$176 billion was direct medical cost while US$69 billion was loss due to reduced productivity.

About TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a fully owned subsidiary of TWi Pharmaceuticals, Inc., is a leading clinical stages biopharmaceutical company based in Taipei, Taiwan, specializing in the development of innovative new drugs for unmet medical needs, especially in the diseases associated with innate immunity. The company is building its product pipeline through in-licensing and internal research. TWi Biotechnology's product development pipeline includes three drug candidates for treating Type II Diabetes, retinopathy, arthritis, and immunodermatology diseases.

Contact:
Michael L. Huang
Head of Investor Relations
Tel: +886-2-2657-3350
Email: michael.huang@twipharma.com


'/>"/>
SOURCE TWi Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
3. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
4. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
5. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
6. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
7. Agricultural Biotechnology: Emerging Technologies and Global Markets
8. Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards
9. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
10. Pharmaceutical Market & Biotechnology Industry 2013 Outlook in New Research Reports at ReportsnReports.com
11. Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017 /PRNewswire/ ... is demonstrating its wireless, handheld ultrasound scanners this ... Gynecologists Annual Scientific Meeting (ACOG) in ... 2017. "Clarius is the perfect ... fetal growth and heart rate, and evaluate pregnancy-related ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career Step company, ... Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The free webinar, ... be presented by Captain Rommie Duckworth, LP, a career fire captain as well as ...
(Date:5/24/2017)... ... May 24, 2017 , ... Adelberg-Montalvan Pediatric Dentistry and ... its patients on Long Island, New York. , Holistic dentistry puts dental ... one of the biggest trends in dentistry today. , Dentist Dr. Marc ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., http://www.FiberstarIngredients.com ... food and beverage industry offers Citri-Fi®, a natural citrus fiber, to improve beverage ... process. As a result, labels need to deliver simple, transparent and clear messaging. ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand ... Integration company, announced today that its iClinic V12.2 solution has achieved approval from ... NCQA recently introduced PCMH 2017 standards which emphasize team-based care with a significant ...
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the premier information ... announced the winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • ... the healthcare industry today. , Out of more than 500 submissions, 100 winners ...
Breaking Medicine News(10 mins):